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S U M M A R Y
Background: Inﬂuenza-like illnesses (ILI) are estimated to cause millions of deaths annually. Despite this
disease burden, the etiologic causes of ILI are poorly described for many geographical regions.
Methods: Beginning in April 2010, we conducted an observational cohort study at ﬁve hospitals in
Mexico City, enrolling subjects who met the criteria for ILI. Evaluations were conducted at enrollment
and on day 28, with the collection of clinical data and a nasopharyngeal swab (or nasal aspirate in
children). Swabs were tested by multiplex PCR for 15 viral pathogens and real-time PCR for inﬂuenza.
Results: During the ﬁrst year, 1065 subjects were enrolled in this study, 55% of whom were hospitalized;
24% of all subjects were children. One or more pathogens were detected by PCR in 64% of subjects, most
commonly rhinovirus (25% of all isolates) and inﬂuenza (24% of isolates). Six percent of subjects died, and
of those, 54% had no pathogen identiﬁed. Rhinovirus was the most common pathogen among those who
died, although it did not have the highest case fatality rate.
Conclusions: Multiple respiratory viruses beyond inﬂuenza are associated with signiﬁcant morbidity and
mortality among adults and children in Mexico City. Detection of these agents could be useful for the
adjustment of antibiotic treatment in severe cases.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
In April 2009, an outbreak of respiratory disease in young
people was reported in Mexico City,1 and the etiologic agent was
identiﬁed as inﬂuenza A virus H1N1pdm09.2 This outbreak and its
consequences compelled the Ministry of Health of Mexico and the
US National Institute of Allergy and Infectious Diseases (NIAID) to
collaborate in establishing a Mexican Emerging Infectious Diseases
Clinical Research Network (La Red).
Acute respiratory infections are estimated to cause 3.9 million
deaths annually,3 many of which are inﬂuenza-like illnesses (ILI).* Corresponding author. Tel.: +52 55 5487 0900 ext. 2420; fax: +52 55 5513 0010.
E-mail address: galindofraga@yahoo.com (A. Galindo-Fraga).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.01.006The etiology of ILI in Mexican individuals seeking medical care is
not well-deﬁned. It has been reported in other populations that
multiple respiratory viruses such as parainﬂuenza virus, rhinovi-
rus, adenovirus, metapneumovirus, respiratory syncytial virus
(RSV), and coronavirus can cause ILI,4 but the virologic etiology
varies greatly among geographic locales, age groups, seasons, and
years.5–13 Some studies have suggested that speciﬁc symptoms
could be used for the clinical prediction of the etiology of ILI,14–18
though most of these studies only compared inﬂuenza to non-
inﬂuenza etiology.
Although the outcomes of subjects infected with various
inﬂuenza subtypes have been well documented,19–21 there is
relatively little description of outcomes from other viral etiologies
of ILI. Shlomai et al. compared outcomes of those hospitalized with
an ILI, and found mortality of 4.6% in inﬂuenza patients vs. 7% inses. Published by Elsevier Ltd. All rights reserved.
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burden that non-inﬂuenza etiological agents contribute to ILIs,
Widmer et al. reported that RSV hospitalization rates exceeded
those of inﬂuenza (15.01 and 11.81 per 10 000, respectively).22
It is important to know the characteristics and seasonal
behavior of the different types of virus causing ILI. Although
current clinical diagnostic tests of all viruses are high in cost,
improved diagnosis would allow a more judicious use of empirical
wide-spectrum antibiotic treatment, which in many cases could be
suspended, and thus reduce the cost of hospitalization.
Recognizing the need to investigate both inﬂuenza and non-
inﬂuenza ILIs in the Mexican population, La Red implemented a
study with the objective of describing the etiology, symptoms, and
outcomes of subjects presenting with ILI in Mexico City.
2. Methods
2.1. Study design and sites
Beginning in April 2010, this hospital-based observational
cohort study was conducted at ﬁve hospitals in Mexico City. These
hospitals are located in the south of Mexico City, and include a
general hospital, a tertiary care hospital that serves mainly those
with respiratory problems, a tertiary care hospital that serves the
metabolic/surgical population, and two pediatric centers. These
centers were chosen given their capacity to conduct clinical
research.
2.2. Case deﬁnition and study population
The study population included subjects aged >3 months who
presented with an ILI. ILI was deﬁned by the presence of at least
one respiratory symptom (e.g., shortness of breath, postnasal
drip, and cough) and one of the two following criteria: (1) fever
(38 8C by any method) on examination, or participant-reported
fever (38 8C), or feverishness in the past 24 h; (2) one or more
non-respiratory symptoms (e.g., malaise, headache, myalgia, and
chest pain). The subjects included were those who sought
medical attention at our centers and agreed to participate in the
study.
2.3. Study procedures
Demographic data were collected at enrollment. A nasopha-
ryngeal swab (Copan, Brescia, Italy), or a nasal aspirate in children,
was obtained for PCR detection of respiratory pathogens andFigure 1. Enrollmentsample storage. The samples were placed in transport medium,
maintained at 4 8C, and sent within 72 h to a central facility
(Molecular Biology Laboratory, Infectious Diseases Department,
INNSZ, Mexico City), where they were stored at 70 8C. Clinical
laboratory tests were carried out at enrollment. If available, the
results of tests taken for standard clinical care (chest X-ray,
bacteriological cultures, arterial blood gases, and liver tests) were
also abstracted from the medical records. Subjects were seen
again on day 28, and follow-up information was also obtained by
phone on days 14 and 60. At each visit, clinical information
(symptoms, chronic medical conditions, previous treatment,
impact on daily function, hospitalizations, and death) was
assessed.
2.4. Virology
All samples were tested by real-time reverse transcriptase PCR
for inﬂuenza A following the Centers for Disease Control and
Prevention (CDC) protocol (CDC 2009), as described previously.23
For multi-pathogen detection, the samples were tested with the
RespiFinder19 kit (previously RespiFinder Plus, from PathoFinder
BV, Maastricht, The Netherlands), as described previously.24 This
multiplex PCR test can detect and differentiate 15 viruses
(coronavirus NL63, OC43, and 229E, human metapneumovirus,
inﬂuenza A, inﬂuenza A H5N1, inﬂuenza B, parainﬂuenza virus
types 1 to 4, RSV A and B, rhinovirus, and adenovirus), as well as
four bacteria (Bordetella pertussis, Chlamydophila pneumoniae,
Legionella pneumophila, and Mycoplasma pneumoniae). The analyt-
ical sensitivity (reported by the manufacturer) varies between 5
and 50 copies per reaction for most targets.25
For the samples with discordant real-time reverse transcriptase
PCR results and multiplex PCR for inﬂuenza, the samples were
further tested with a third method, based on a ﬁnal-point nested
PCR protocol.26 For these samples, the result of this test was
considered the ﬁnal result.
2.5. Statistical analysis
Data were analyzed with the Statistical Analysis System (SAS
Institute, Cary, NC, USA). Median (range) and percentage were used
to summarize quantitative and qualitative variables, respectively.
To discard the role of chance, the Mann–Whitney test and the Chi-
square or Fisher’s exact test were used as appropriate. Univariate
logistic regression analyses were performed to evaluate the effect
of each baseline covariate on the risk of death. Odds ratios (OR) and
the corresponding 95% conﬁdence intervals (CI) were reported and follow-up.
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two-sided, with no correction for multiple comparisons; p < 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Patients
From April 11, 2010 through April 10, 2011, 1065 subjects were
enrolled in this study. A total of 86 withdrew or were withdrawn
from the study (Figure 1). Characteristics of the study participants
are listed in Table 1. Just under a quarter of the study subjects were
children and 58.8% were female. Four hundred thirty-six (40.9%)
subjects were hospitalized. Asthma and cardiovascular disease
were the most common chronic medical conditions, though
neither condition accounted for more than 17% of subjects.
3.2. Etiology
A total of 821 etiologic agents were identiﬁed among the 678
(64% of total) subjects from whom a pathogen was isolated.
Rhinovirus was the most frequently isolated pathogen, infecting
15.3% of enrolled subjects and accounting for 25.3% of all isolates.
Rhinovirus was followed by inﬂuenza, which was detected in
14.3% of subjects, and 24% of isolates. Adenovirus, coronavirus,
metapneumovirus, and RSV all had an isolate frequency of 9% or
greater. No pathogen was detected for 35.5% of subjects
(Table 2).
Among the 125 subjects (11.9%) with mixed virus infections, 62
unique combinations were recorded. The most common combina-
tions were adenovirus/rhinovirus in nine subjects (7.2% of
combinations), adenovirus/metapneumovirus in eight subjects
(6.4%), and inﬂuenza B/metapneumovirus in eight subjects (6.4%).Table 1
Baseline characteristics
Demographics Total, N = 1065 
Age, years
Median 33
Range 0–96
18 262 (24.6%)
19–59 614 (57.6%)
60 189 (17.8%)
Sex
Male 439 (41.2%) 
Female 626 (58.8%) 
Pregnant 4 
Ethnicity
Mixed 1026 (96.4%) 
White 33 (3.1%) 
Other 5 (0.5%) 
Medical history
Inﬂuenza vaccination 504 (47.3%) 
Asthma 151 (14.2%) 
CVD 147 (13.8%) 
Diabetes 99 (9.3%) 
Immunodeﬁciency 48 (4.5%) 
Renal disorder 42 (3.9%) 
COPD 36 (3.4%) 
BMI categorya
Obese 207 (19.9%) 
Overweight 313 (30.2%) 
Normal 417 (40.2%) 
Underweight 101 (9.7%) 
Median days since symptoms onset 1
Inpatient at baseline 436 (40.9%) 
Outpatient at baseline 629 (59.1%) 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovasc
a BMI categories: underweight = BMI < 18.5 kg/m2 (or <1 SD for children); normal weig
of 30 kg/m2 (>2 SD for children).Inﬂuenza was the most common virus involved in co-infections
(when considering all subtypes), present in 45/125 (36%)
combinations. Most combinations were limited to two viruses.
3.3. Seasonal distribution of viruses
The four most common pathogens (rhinovirus, inﬂuenza,
coronavirus, and RSV) all had seasonal distributions with more
isolates observed during cooler months (December–March). The
seasonal variation of rhinovirus and RSV, however, was less
pronounced than that of coronavirus and inﬂuenza (Figure 2).
During April – November, rhinovirus accounted for 20–60% of all
ILI. However, between December and March – a period during
which the total number of ILI cases increased – the relative
contribution of rhinovirus to ILI was only 10–20%.
3.4. Vaccination
Previous inﬂuenza vaccination was reported for 46.2% of the
children and 47.7% of the adults. We found no difference in the
proportion of vaccinated and unvaccinated subjects in the persons
with virus or without virus detection, neither for individual agents
nor as a group.
3.5. Symptoms
Evaluation across the four most common pathogens showed
that children were more likely to have fever, productive cough, and
nausea, whereas adults were more likely to have fatigue, headache,
and sore throat (Table 3). Respiratory symptoms, such as dyspnea,
were more common among those with rhinovirus or RSV, and
gastrointestinal symptoms, such as nausea or diarrhea, were more
common among those with inﬂuenza.Children, n = 262 Adults, n = 803
132 (50.4%) 307 (38.2%)
130 (49.6%) 496 (61.8%)
4
252 (96.2%) 775 (96.5%)
10 (3.8%) 23 (2.9%)
5 (0.6%)
121 (46.2%) 383 (47.7%)
16 (6.1%) 135 (16.8%)
17 (6.5%) 130 (16.2%)
99 (12.3%)
8 (3.1%) 40 (5.0%)
4 (1.5%) 38 (4.8%)
36 (4.5%)
23 (9.2%) 184 (23.3%)
42 (16.1%) 273 (34.6%)
121 (48.6%) 296 (37.5%)
65 (26.1%) 36 (4.6%)
113 (43.1%) 323 (40.2%)
149 (56.9%) 480 (59.8)
ular disease; SD, standard deviation.
ht = 18.5–24.9 kg/m2; overweight = 25–29.9 kg/m2 (>1SD for children); obese = BMI
Table 2
Frequency distribution of viral isolates
Pathogen Age <18a, n (%) Age 18–59a, n (%) Age 60a, n (%) Totala, n (%) Totalb, n (%)
Adenovirus 17 (6.6) 15 (2.5) 3 (1.6) 35 (3.3) 74 (9.0)
Bordetella pertussis 2 (0.8) 3 (0.5) 0 (0) 5 (0.5) 9 (1.1)
Coronavirus 12 (4.7) 50 (8.2) 15 (8.2) 77 (7.3) 118 (14.4)
229E 0 11 2 13 22
NL63 2 8 1 11 18
OC43 10 31 12 53 78
Inﬂuenza 43 (16.7) 89 (14.6) 18 (9.8) 150 (14.3) 197 (24.0)
A 3 5 0 8 11
A H1N1 2009 0 5 1 6 7
A H3N2 16 46 11 73 91
B 24 33 6 63 88
Metapneumovirus 11 (4.3) 22 (3.6) 9 (4.9) 42 (4.0) 78 (9.5)
Mycoplasma pneumoniae 1 (0.4) 4 (0.7) 1 (0.5) 6 (0.6) 10 (1.2)
Parainﬂuenza virus 6 (2.3) 12 (1.9) 2 (1.1) 20 (1.9) 42 (5.1)
1 0 0 0 0 3
2 0 0 0 0 3
3 6 7 1 14 24
4 0 5 1 6 12
Rhinovirus 29 (11.2) 100 (16.4) 32 (17.4) 161 (15.3) 208 (25.3)
RSV 34 (13.2) 15 (2.5) 8 (4.3) 57 (5.4) 85 (10.3)
A 33 15 6 54 72
B 1 0 2 3 13
Mixed infections 51 (19.8) 60 (9.9) 14 (7.6) 125 (11.9)
Negative cases 52 (20.2) 238 (39.1) 83 (45.1) 373 (35.5)
Total 258 (100) 609 (100) 184 (100) 1051 (100)c 821 (100)
RSV, respiratory syncytial virus.
a Frequency by subject. Infections with more than one virus are counted as a single category (mixed infection).
b Frequency by isolates. Excludes negative cases.
c Fourteen subjects did not have a baseline sample for virologic testing.
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Hospitalization was required for 585 subjects (54.9%) (Table 4).
A lower percentage of subjects infected with coronavirus and
inﬂuenza were hospitalized (32% and 29%) than those infected
with rhinovirus and RSV (51% and 56%, respectively) (Table 3). In
the pediatric population, RSV infections had the highest rate of
hospitalization (76.5%), as well as the highest absolute number of
hospitalizations (n = 26, 24.4% of all hospitalized pediatric sub-
jects). Mixed infections (n = 25, 20.7%), rhinovirus (n = 17, 14.0%),
and inﬂuenza (n = 11, 9.1%) also contributed signiﬁcantly to
hospitalization in the pediatric cohort. Rhinovirus was also the
most common pathogen isolated from adults and the elderly who
were hospitalized, followed by mixed infections, inﬂuenza, and
metapneumovirus.
Of the 1065 patients enrolled, 66 died (6.2%). Of the patients
who died, 54% had no pathogen identiﬁed. Rhinovirus was the
most common etiologic agent identiﬁed in subjects who died
(37.9% of deaths with a pathogen identiﬁed, and 17.5% of all
deaths). Only four pediatric subjects died: two with RSV, one with
parainﬂuenza, and one with Mycoplasma. Subjects 60 years of
age infected with coronavirus, inﬂuenza, metapneumovirus,
rhinovirus, or RSV all had mortality rates exceeding 10%. The
highest mortality rate (27.7%, n = 23) was seen in the cohort of
patients 60 years old with no identiﬁed pathogen, followed by
rhinovirus. Mixed viral infections did not have an appreciably
larger rate of hospitalization or death.
Subjects who died were more likely to have elevated creatinine,
lactate dehydrogenase, and C-reactive protein, lower lymphocyte
counts, and higher neutrophil counts (Table 5). Subjects who died
were more likely to have underlying medical conditions (except
asthma). Subjects on systemic steroids prior to enrollment were
also more likely to die. Headaches and sore throats were seen more
commonly in non-fatal cases, whereas rales (representing lower
respiratory tract disease) were more likely in fatal cases. Aproductive cough did not seem to differentiate fatal from non-fatal
cases.
4. Discussion
This study presents the most thorough description of the causes
of ILI in Mexico City to date. Using a multiplex PCR test, one or more
pathogens were identiﬁed in 65% of enrolled subjects. The most
common pathogen identiﬁed in the study was rhinovirus (25% of
all isolates), and inﬂuenza was the second most common pathogen
(24% of all isolates). This is consistent with other series of adult ILI
in various geographic regions, where rhinovirus has been reported
to account for 25–50% of adult ILI isolates, and inﬂuenza for 14–
23%.10,13,27,28 Coronavirus – most commonly OC43, but also NL63
and 2229E – was also a signiﬁcant contributor to the burden of ILI
(14% of all isolates). Recent studies have reported coronavirus to be
the third to ﬁfth most common pathogen.10,13
Among children in this study, the most common pathogen was
inﬂuenza, followed by RSV and rhinovirus. Similar signiﬁcant
contributions of RSV and inﬂuenza have been noted in prior
studies.29–31 Rhinovirus, however, was rarely tested in previous
studies. In one other prospective cohort study of children with
lower respiratory tract infections, rhinovirus was reported as
second only to RSV in causing hospitalizations.32 The frequency at
which it was isolated in our hospitalized children (14%, 17/121)
suggests that rhinovirus is a previously under-appreciated
pathogen for this age group.
Rhinovirus was a cause of signiﬁcant morbidity in all age groups
of our study population, such that 60–80% of individuals infected
with rhinovirus required hospitalization. Rhinovirus was also the
most common isolate from subjects who died (isolated from 11/66
subjects). Given the study design, a clear attribution to the cause of
hospitalization or death is not possible.
Coronavirus species made up 14% of all isolates in our
population. Coronavirus can present with a similar syndrome to
Figure 2. Monthly distribution of viral isolates. Total monthly enrollment (line), and the four most prevalent viruses (A). Monthly isolates by virus subtype (bars) and percent
positive are demonstrated for the ﬁve most common viruses: inﬂuenza (B), coronavirus (C), respiratory syncytial virus (D), metapneumovirus (E), and rhinovirus (F).
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coronavirus were hospitalized, but in the population aged 60
years this increased to 73%. While our study design precludes the
determination of exact hospitalization rates as a result of
coronavirus infections, the hospitalization rates were similar to
those for inﬂuenza.
No pathogen was identiﬁed in 35% of subjects. This was more
common in adults (no pathogen detected in 41% (321/793) of all
adult subjects aged 18 years) than in children (no pathogen
detected in 20% of subjects). It is unclear if these subjects had
bacterial infections, pathogens not tested for in our assay, or non-
infectious etiologies of their ILI. Unfortunately the lack of pairedsputum limited our ability to determine etiology. In a cohort in
New Caledonia, paired sputum samples were required to deter-
mine the etiologic agent in 23% of subjects with lower respiratory
tract infections.32 In a population of hospitalized children in
Mexico with lower respiratory tract infections, viral etiologies
were determined in only 47%.34 This study found a virologic agent
in 80% of children. This improved detection is likely in part due to
the extended panel of viruses that were tested with the multiplex
PCR.
More than one virus was isolated in 11.9% of subjects. It is not
possible to determine the contribution of each virus to the clinical
syndrome, nor is it possible to determine if some viruses that were
Table 3
Demographics and symptoms by age and pathogen
Children Adults
Coronavirus Inﬂuenza Rhinovirus RSV Coronavirus Inﬂuenza Rhinovirus RSV
Number enrolled 12 43 29 34 65 107 132 23
Any antiviral 0% 9% 7% 6% 28% 33% 27% 35%
Chronic medical condition 42% 28% 38% 26% 42% 44% 63% 74%
Asthma 8% 7% 10% 3% 11% 21% 19% 26%
CVD 0% 0% 10% 6% 15% 10% 20% 17%
COPD 0% 0% 0% 0% 5% 6% 2% 13%
DM 0% 0% 0% 0% 8% 6% 19% 13%
Antibiotics 50% 44% 52% 71% 40% 48% 66% 65%
Inhaled steroids 8% 9% 21% 24% 18% 20% 14% 35%
Systemic steroids 25% 9% 17% 21% 22% 24% 28% 43%
Pregnant 0% 0% 0% 0% 0% 1% 0% 0%
Non-smoker 0% 0% 0% 0% 72% 51% 60% 65%
Current/former smoker 0% 0% 0% 0% 28% 49% 40% 35%
Seasonal ﬂu vaccine 50% 47% 45% 38% 60% 39% 39% 52%
Outpatient 67% 81% 38% 35% 68% 67% 52% 57%
Hospitalized 33% 19% 62% 65% 32% 33% 48% 43%
Symptoms
Rales/crepitations 33% 16% 55% 79% 25% 29% 39% 26%
Wheezing 25% 16% 21% 29% 12% 22% 25% 35%
Fever 67% 95% 69% 100% 45% 79% 65% 70%
Productive cough 75% 65% 83% 88% 52% 59% 58% 57%
Diarrhea 0% 9% 0% 12% 6% 11% 4% 4%
Dyspnea 0% 16% 31% 38% 22% 33% 39% 43%
Fatigue 0% 58% 34% 32% 71% 64% 41% 57%
Headache 0% 51% 21% 12% 74% 75% 55% 39%
Nausea 17% 42% 14% 24% 15% 21% 9% 22%
Red eyes 0% 49% 17% 9% 37% 27% 13% 17%
Sore throat 25% 60% 14% 15% 65% 61% 47% 52%
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; RSV, respiratory syncytial virus.
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improves the sensitivity of detecting respiratory viruses, the
detection of viral nucleic acids may not always represent
causation. In prior case–control studies, virus nucleic acids could
be isolated from 20–27% of asymptomatic subjects.35,36 This might
be supported by the data showing that among those with mixed
infections, the outcomes were not signiﬁcantly worse than thoseTable 4
Hospitalizations and deaths by pathogen
Pathogen Hospitalized % (n) 
Age <18 Age 18–59 
Adenovirus 41.8% (7) 66.7% (10) 
Bordetella pertussis 100% (2) 33.3% (1)
Coronavirus 33.3% (4) 24% (12) 
229E 45.5% (5) 
NL63 25% (2) 
OC43 40% (4) 16.1% (5) 
Inﬂuenza 25.6% (11) 43.8% (39) 
A 60% (3)
A H1N1 2009 80% (4)
A H3N2 25% (4) 50% (23) 
B 29.2% (7) 27.3% (9) 
Metapneumovirus 63.6% (7) 50% (11) 
Mycoplasma pneumoniae 100% (4) 100% (1) 
Parainﬂuenza virus 66.7% (4) 41.7% (5) 
1
2
3 66.7% (4) 42.9% (3) 
4 40% (2) 
Rhinovirus 58.6% (17) 59% (59) 
Respiratory syncytial virus 76.5% (26) 53.3% (8) 
A 75.8% (25) 53.3% (8) 
B 100% (1) 
Mixed infections 49% (25) 56.7% (34) 
Negative cases 34.6% (18) 51.7% (123) 
Total 46.2% (121) 49.8% (306) for subjects with single infections. While all subjects enrolled were
symptomatic, and this would increase the likelihood that isolated
pathogens were causative, cohort studies such as ours are not able
to directly determine causation. With 62 unique combinations in
125 different subjects, the assessment of outcomes lacks statistical
power to determine differences between the various combinations
of mixed infections.Death % (n)
Age 60 Age <18 Age 18–59 Age 60
100% (3) 6.7% (1)
73.3% (11) 2% (1) 13.3% (2)
100% (2)
100% (1)
66.7% (8) 3.2% (1) 16.7% (2)
72.2% (13) 11.1% (2)
72.7% (8) 9.1% (1)
83.3% (5) 16.7% (1)
88.9% (8) 22.2% (2)
100% (1)
100% (2) 16.7% (1)
100% (1) 16.7% (1)
100% (1)
81.3% (26) 7% (7) 12.5% (4)
100% (8) 5.9% (2) 25% (2)
100% (6) 6.1% (2) 33.3% (2)
100% (2)
100% (14) 10% (6) 7.1% (1)
88% (73) 4.6% (11) 27.7% (23)
84.1% (159) 1.5% (4) 4.2% (26) 19% (36)
Table 5
Outcomes
Variable at baseline Patients who survived Patients who died Odds ratio p-Value
Median (range), n = 999 Median (range), n = 66 Estimate (95% CI)
Creatinine phosphokinase (U/l) 95 (9–7160) 90.5 (10–1840) 1.04 (1.00, 1.08) 0.066
Creatinine (mg/dl) 0.6 (0–14) 1.1 (0.1–9.7) 1.37 (1.19, 1.58) <0.001
C-reactive protein (mg/l) 1.4 (0–36) 14.25 (1.6–34.1) 1.12 (1.09, 1.16) <0.001
Hematocrit (%) 41.7 (14.3–76.1) 34.9 (13.2–57.5) 0.73 (0.66, 0.8) <0.001
Hemoglobin (g/dl) 14.1 (4.1–25.4) 11.7 (4.7–19) 0.73 (0.66, 0.8) <0.001
Lactate dehydrogenase (IU/l) 224 (26–4003) 338 (31–5175) 1.19 (1.08, 1.32) 0.001
Lymph (%) 18 (0–92) 7 (1–35) 0.92 (0.90, 0.95) <0.001
Lymph absolute (109/l) 1.4 (0–35.1) 0.7 (0.02–6.8) 0.92 (0.88, 0.95) <0.001
Neutrophil (%) 70 (0–97) 87 (16–98) 1.06 (1.04, 1.08) <0.001
Neutrophil absolute (109/l) 5.7 (0–26.9) 8.6 (0.27–27.2) 1.01 (1.00, 1.01) 0.001a
Platelets (109/l) 231 (10–744) 140 (3–551) 0.91 (0.88, 0.94) <0.001
White blood count (109/l) 8.5 (0.1–54) 10.4 (0.3–29.2) 1.03 (0.99, 1.07) 0.179
Patients who survived Patients who died Odds ratio p-Value
Percent Percent Estimate (95% CI)
Any antiviral medications 21.2 39.4 2.41 (1.44, 4.05) <0.001a
Inhaled steroids 18.4 18.2 1.00 (0.52, 1.91) 1.00
Systemic steroids 23.7 36.4 1.88 (1.11, 3.1) 0.02
History of smoking 30.3 50.0 2.30 (1.39, 3.79) <0.001a
Medical history
Asthma 15.0 1.5 0.09 (0.01, 0.63) 0.02a
Cardiovascular disorder 12.7 30.3 2.99 (1.71, 5.21) <0.001a
COPD 3.0 9.1 3.23 (1.29, 8.06) 0.01a
Diabetes 8.7 18.2 2.33 (1.20, 4.52) 0.01
Immunodeﬁciency 3.7 16.7 5.20 (2.52, 10.75) <0.001
Renal disorder 3.5 10.6 3.27 (1.39, 7.67) 0.01a
Signs and symptoms
Productive cough 62.9 51.5 0.63 (0.38, 1.03) 0.07
Diarrhea 7.5 3.0 0.39 (0.09, 1.60) 0.19
Dyspnea 32.5 39.4 1.35 (0.81, 2.25) 0.25
Fatigue 51.8 42.4 0.69 (0.42, 1.14) 0.14
Fever 70.9 75.8 1.28 (0.72, 2.29) 0.40
Headache 53.2 21.2 0.24 (0.13, 0.43) <0.001
Nausea 18.9 1.5 0.07 (0.01, 0.48) 0.01a
Rales/crepitations 36.7 83.3 8.61 (4.45, 16.66) <0.001
Red eyes 21.6 4.5 0.17 (0.05, 0.56) <0.001a
Sore throat 46.4 21.2 0.31 (0.17, 0.57) <0.001
Wheezing 23.2 9.1 0.33 (0.14, 0.78) 0.01a
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease.
a When analysis for deaths attributed to ILI, the p-value was no longer <0.05.
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has several implications. First, increasing knowledge that acute
respiratory illness and its associated morbidity are often caused by
respiratory viruses may stimulate the development of more
affordable rapid diagnostic tests as well as therapeutics for these
viruses. With the consideration of increasing antibiotic resistance,
the diagnosis of respiratory viruses could decrease the quantities of
empiric broad-spectrum antibiotics used.
The aim of this study was not the epidemiological surveillance
of respiratory diseases. We included only patients who by the
severity of their illnesses sought medical attention. The attending
physicians determined the need for hospitalization or outpatient
treatment. This limited our population to a particular group of
patients with clinical manifestations of the disease. With this
strategy we seek to ﬁnd the more serious cases. From this we
believe we can more easily determine the factors associated with
severe disease. It is a limitation of this study, however, that we lose
a part of the population with mild or asymptomatic disease.
In conclusion, viruses that were traditionally believed to produce
minor disease have the capacity, in certain subjects, to cause severe
cases, as suggested by the high proportion of adult patients with
rhinovirus infection who required in-hospital treatment. We believe
that these ﬁndings mark the need for speciﬁc studies that will help
us to better understand the behavior of these viruses, and the factors
associated with a more serious presentation.Acknowledgements
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